Interleukin-8 and depressive responses to an inflammatory challenge: secondary analysis of a randomized controlled trial
Year: 2022
Type: article
Abstract: Emerging evidence suggests that interleukin (IL)-8 has a protective role in the context of depression. Higher levels of IL-8 are associated with lower depressive symptom severity among depressed patients, and treatment-related increases in IL-8 correlate with a positive response in depressed patients. This study (a secondary analysis of a completed randomized controlled trial) aimed to examine whether higher levels of IL-8 mitigate increases in depressed mood in response to an experimental model of inflammation induced depression. Given epidemiologic relationships identified between IL-6, tumor necrosis factor (TNF)- α, and subsequent depression, levels of these pro-inflammatory cytokines were also explored as potential moderators of depressed mood response to endotoxin. Secondary analyses were completed on data from healthy adults (n = 114) who completed a double-blind, placebo-controlled randomized trial in which participants were randomly assigned to receive either a single infusion of low-dose endotoxin (derived from Escherichia coli; 0.8 ng/kg of body weight) or placebo (same volume of 0.9% saline). IL-8, as well as IL-6 and TNF- α, were measured at baseline prior to infusion, and depressed mood and feelings of social disconnection were assessed approximately hourly. Baseline levels of IL-8, but not IL-6 or TNF-α, moderated depressed mood (β = - 0.274, p = .03) and feelings of social disconnection (β = - 0.307, p = .01) responses, such that higher baseline IL-8 was associated with less increase in depressed mood and feelings of social disconnection in the endotoxin, but not placebo, condition. IL-8 had threshold effects, in which highest quartile IL-8 (≥ 2.7 pg/mL) attenuated increases in depressed mood in response to endotoxin as compared to lower IL-8 quartiles (p = .02). These findings suggest that IL-8 may be a biological factor that mitigates risk of inflammation-associated depression. Clinical trials registration: ClinicalTrials.gov NCT01671150, registration date 23/08/2012.
Source: Scientific Reports
Authors: Jennifer L. Kruse, Chloe C. Boyle, Richard Olmstead, Elizabeth C. Breen, Susannah J. Tye, Naomi I. Eisenberger, Michael R. Irwin
Language: English
Subfield: Biological Psychiatry
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,190
Funders: National Institutes of Health, National Institute on Aging, National Heart, Lung, and Blood Institute, National Institute of Mental Health, National Institute on Drug Abuse, National Cancer Institute, National Center for Advancing Translational Sciences, Norman Cousins Center for Psychoneuroimmunology, Clinical and Translational Science Institute, University of California, Los Angeles
Awards: Aging: Sleep and Inflammatory Mechanisms in Depression Prevention, Social Isolation and Sleep Disturance in Aging: Inflammatory Mechanisms, Sleep, Inflamation, and Depression Occurrence in Breast Cancer Survivors, Depression Response to Fast-Acting Treatments: Inflammation and Reward Mechanisms, G562934659, Inflammation-Induced Depressed Mood: The Role of Social Neurocognitive Mechanisms, Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms, UCLA Clinical and Translational Science Institute, Mechanisms of Sleep Disruption Hyperalgesia, Chronic Moderate Sleep Restriction in Older Long and Older Average Sleepers
OpenAlex ID: W4286801079
